EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Genomic and Clinical Features Associated With Reduced Susceptibility to Cefiderocol and Cross-Resistance to β-Lactam/β-Lactamase Inhibitors in a Global Cohort of Pseudomonas aeruginosa

Stephanie L Egge iD, Donghoon Kang iD, Nazanin Pouya, Philip C Thornton, Erika Flores, Karim Clarke, Max W Adelman iD, Cornelius L Rosenbaum, Rodrigo P Baptista iD, Cesar A Arias iD, Vincent H Tam iD, Michael J Satlin iD und 1 weitere

The Journal of Infectious Diseases · 15.10.2026 · 234 (4) · e985-e995

DOI: 10.1093/infdis/jiag263 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 15.05.2026. Verfasst von Stephanie L Egge und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, beta-Lactamase Inhibitors, Cefiderocol, Cephalosporins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, NIAID NIH HHS, Melinta.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cefiderocol retains high rates of activity against carbapenem-resistant P. aeruginosa (CRPA) and is being introduced as a last resort antibiotic in developing countries. This study assessed the clinical and genotypic characteristics associated with decreased cefiderocol susceptibility among a global collection of CRPA isolates.

Methods

Clinical isolates (n = 186) selected from 972 patients enrolled from 10 countries as part of the Prospective Observational Pseudomonas (POP) study were characterized by whole-genome sequencing, cefiderocol broth microdilution, and population analysis profile. We compared clinical and genomic characteristics between susceptible isolates and those with reduced cefiderocol susceptibility (defined as heteroresistant by population analysis, or intermediate or resistant using current breakpoints). A hollow fiber infection model was used to evaluate the emergence of resistance under human serum simulated cefiderocol exposures.

Results

Of the 186 isolates, 11 (5.9%) were cefiderocol nonsusceptible and 28 (15.1%) were heteroresistant using CLSI breakpoints. With EUCAST breakpoints, 20 (10.8%) were cefiderocol resistant and 20 (10.8%) were heteroresistant. Reduced susceptibility isolates were present across all geographic regions and harbored changes in PirRS-regulated siderophore receptors, AmpC β-lactamase mutations associated with decreased ceftolozane/tazobactam susceptibility, cpxS mutations, and the β-lactamases blaNDM and blaVEB. Resistance to ceftolozane/tazobactam and ceftazidime/avibactam were independently associated with reduced cefiderocol susceptibility. Cefiderocol resistance emerged in a heteroresistant, but not susceptible isolate at human simulated exposures.

Conclusions

Decreased cefiderocol susceptibility is present worldwide and is not restricted to a clonal high-risk lineage. This raises concerns about the use of cefiderocol as a salvage regimen in patients with multidrug-resistant P. aeruginosa infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial Agentsbeta-Lactamase InhibitorsCefiderocolCephalosporinsDrug Resistance, Multiple, BacterialPseudomonas aeruginosaPseudomonas InfectionsAdultAgedFemaleHumansMaleMiddle AgedCeftazidimeMicrobial Sensitivity TestsProspective StudiesThird Generation CephalosporinsWhole Genome SequencingDrug CombinationsAzabicyclo Compounds

Stichwörter der Autor:innen

Pseudomonas aeruginosaantibiotic heteroresistancecefiderocolceftazidime-avibactamceftolozane/tazobactam

Substanzen

Anti-Bacterial Agentsavibactam, ceftazidime drug combinationbeta-Lactamase InhibitorsCefiderocolCeftazidimeCephalosporinsThird Generation CephalosporinsDrug CombinationsAzabicyclo Compounds

Autor:innen und Institutionen

  • Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
  • Center for Infectious Diseases, Houston Methodist Research Institute, Houston, Texas, USA.
  • Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA.
  • Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
  • Center of Health Data Science and Analytics, Houston Methodist, Houston, Texas, USA.

ORCID-Profile: Stephanie L Egge, Donghoon Kang, Max W Adelman, Rodrigo P Baptista, Cesar A Arias, Vincent H Tam, Michael J Satlin, William R Miller

Förderung

  • National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS
  • Melinta
  • NIH/NIAID
  • Ansun Biopharma
  • Merck
  • Cystic Fibrosis Foundation
  • Gulf Coast Consortia, Antimicrobial Resistance Training Program in the Texas Medical Center (TPT-AMR) (NIAID)

Zitieren

APA

Egge, S. L., Kang, D., Pouya, N., Thornton, P. C., Flores, E., Clarke, K., Adelman, M. W., Rosenbaum, C. L., Baptista, R. P., Arias, C. A., Tam, V. H., Satlin, M. J., & Miller, W. R. (2026). Genomic and Clinical Features Associated With Reduced Susceptibility to Cefiderocol and Cross-Resistance to β-Lactam/β-Lactamase Inhibitors in a Global Cohort of Pseudomonas aeruginosa. The Journal of Infectious Diseases, 234(4), e985-e995. https://doi.org/10.1093/infdis/jiag263

Vancouver

Egge SL, Kang D, Pouya N, Thornton PC, Flores E, Clarke K, et al. Genomic and Clinical Features Associated With Reduced Susceptibility to Cefiderocol and Cross-Resistance to β-Lactam/β-Lactamase Inhibitors in a Global Cohort of Pseudomonas aeruginosa. The Journal of Infectious Diseases. 2026;234(4):e985-e995. doi:10.1093/infdis/jiag263

BibTeX
@article{Egge2026,
  author = {Egge, Stephanie L and Kang, Donghoon and Pouya, Nazanin and Thornton, Philip C and Flores, Erika and Clarke, Karim and Adelman, Max W and Rosenbaum, Cornelius L and Baptista, Rodrigo P and Arias, Cesar A and Tam, Vincent H and Satlin, Michael J and Miller, William R},
  title = {Genomic and Clinical Features Associated With Reduced Susceptibility to Cefiderocol and Cross-Resistance to β-Lactam/β-Lactamase Inhibitors in a Global Cohort of Pseudomonas aeruginosa},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  volume = {234},
  number = {4},
  pages = {e985--e995},
  doi = {10.1093/infdis/jiag263}
}
Kostenlos starten →